FRONTIERS 润色咨询

FRONTIERS-A JOURNAL OF WOMEN STUDIES

出版年份：暂无数据 年文章数：503 投稿命中率： 开通期刊会员，数据随心看

出版周期：暂无数据 自引率：暂无数据 审稿周期： 开通期刊会员，数据随心看

前往期刊查询
期刊讨论 | 中国SCI论文 | 期刊主页 | 投稿经验 | 杂志官网 | 投稿链接 | 作者需知 | PMC链接 | Pubmed全文检索

期刊讨论

  1. [GetPortalCommentsPageByObjectIdResponse(id=2113825, encodeId=96db2113825b8, content=审稿速度:1.0 | 投稿命中率:75.0<br>偏重的研究方向：medical;hematology;lymphoma<br>经验分享：We'll get a response soon after we put it in., beContent=null, objectType=tool_impact_factor, channel=null, level=null, likeNumber=31, replyNumber=1, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=040f4154734, createdName=787453003, createdTime=Thu Feb 09 17:35:45 CST 2023, time=2023-02-09, status=1, ipAttribution=四川省), GetPortalCommentsPageByObjectIdResponse(id=1113098, encodeId=4fb31113098c4, content=什么是Protocol？, beContent=null, objectType=tool_impact_factor, channel=null, level=null, likeNumber=40, replyNumber=2, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=/v1.0.0/img/user_icon.png, createdBy=bb142989248, createdName=MS68862005, createdTime=Mon Dec 27 14:52:55 CST 2021, time=2021-12-27, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1113097, encodeId=1241111309e0c, content=什么是comment？, beContent=null, objectType=tool_impact_factor, channel=null, level=null, likeNumber=39, replyNumber=2, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=https://img.medsci.cn/20220301/3a52d3952dde49019f1e000bb5c41d1c/0a0eb7959bb14fcd87745f869bee3c33.jpg, createdBy=46f32239729, createdName=Mia, createdTime=Wed Dec 29 14:52:55 CST 2021, time=2021-12-29, status=1, ipAttribution=)]
    2023-02-09 787453003 来自四川省

    审稿速度:1.0 | 投稿命中率:75.0
    偏重的研究方向：medical;hematology;lymphoma
    经验分享：We'll get a response soon after we put it in.

    1

    展开1条回复
  2. [GetPortalCommentsPageByObjectIdResponse(id=2113825, encodeId=96db2113825b8, content=审稿速度:1.0 | 投稿命中率:75.0<br>偏重的研究方向：medical;hematology;lymphoma<br>经验分享：We'll get a response soon after we put it in., beContent=null, objectType=tool_impact_factor, channel=null, level=null, likeNumber=31, replyNumber=1, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=040f4154734, createdName=787453003, createdTime=Thu Feb 09 17:35:45 CST 2023, time=2023-02-09, status=1, ipAttribution=四川省), GetPortalCommentsPageByObjectIdResponse(id=1113098, encodeId=4fb31113098c4, content=什么是Protocol？, beContent=null, objectType=tool_impact_factor, channel=null, level=null, likeNumber=40, replyNumber=2, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=/v1.0.0/img/user_icon.png, createdBy=bb142989248, createdName=MS68862005, createdTime=Mon Dec 27 14:52:55 CST 2021, time=2021-12-27, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1113097, encodeId=1241111309e0c, content=什么是comment？, beContent=null, objectType=tool_impact_factor, channel=null, level=null, likeNumber=39, replyNumber=2, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=https://img.medsci.cn/20220301/3a52d3952dde49019f1e000bb5c41d1c/0a0eb7959bb14fcd87745f869bee3c33.jpg, createdBy=46f32239729, createdName=Mia, createdTime=Wed Dec 29 14:52:55 CST 2021, time=2021-12-29, status=1, ipAttribution=)]
    2021-12-27 MS68862005

    什么是Protocol？

    2

    展开2条回复
  3. [GetPortalCommentsPageByObjectIdResponse(id=2113825, encodeId=96db2113825b8, content=审稿速度:1.0 | 投稿命中率:75.0<br>偏重的研究方向：medical;hematology;lymphoma<br>经验分享：We'll get a response soon after we put it in., beContent=null, objectType=tool_impact_factor, channel=null, level=null, likeNumber=31, replyNumber=1, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=040f4154734, createdName=787453003, createdTime=Thu Feb 09 17:35:45 CST 2023, time=2023-02-09, status=1, ipAttribution=四川省), GetPortalCommentsPageByObjectIdResponse(id=1113098, encodeId=4fb31113098c4, content=什么是Protocol？, beContent=null, objectType=tool_impact_factor, channel=null, level=null, likeNumber=40, replyNumber=2, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=/v1.0.0/img/user_icon.png, createdBy=bb142989248, createdName=MS68862005, createdTime=Mon Dec 27 14:52:55 CST 2021, time=2021-12-27, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1113097, encodeId=1241111309e0c, content=什么是comment？, beContent=null, objectType=tool_impact_factor, channel=null, level=null, likeNumber=39, replyNumber=2, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=https://img.medsci.cn/20220301/3a52d3952dde49019f1e000bb5c41d1c/0a0eb7959bb14fcd87745f869bee3c33.jpg, createdBy=46f32239729, createdName=Mia, createdTime=Wed Dec 29 14:52:55 CST 2021, time=2021-12-29, status=1, ipAttribution=)]
    2021-12-29 Mia

    什么是comment？

    2

    展开2条回复
共8条页码: 1/1页10条/页
分享您的投稿经验，提升MI经验值，获取更多积分